A New Hope for Treatment-Resistant Multiple Myeloma: CellCentric Advances InoPd into Pivotal Clinical Testing
- April 7, 2026
Gilead Ends Midstage HIV Study as FDA Clinical Hold Continues
Can We Fix This Broken Heart? – Part 1
Draft Guidance from FDA Introduces Important Changes to Drug Development for Rare Diseases
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
A New Hope for Treatment-Resistant Multiple Myeloma: CellCentric Advances InoPd into Pivotal Clinical Testing bit.ly/4slMlDA Read now at PatientWorthy.com
#PatientWorthy #multiplemyeloma #rrmm #clinicaltrials
Bohring-Optiz Syndrome (BOS) is a rare genetic disorder that impacts growth and development, often associated with feeding difficulties, developmental delays, and distinct physical characteristics. While uncommon, it has a profound impact on individuals and families within the BOS community.
Observed annually on April 6th, Bohring-Optiz Syndrome Awareness Day is dedicated to increasing understanding, supporting affected families, and advancing research. By raising awareness, we help foster greater recognition, compassion, and process toward improved care and outcomes.
Share your rare disease journey and inspire others here: bit.ly/4dV7gru
#bohring-OptizSyndrome #BOSAwarenessDay #PatientWorthy
Throughout the week, Patient Worthy is highlighting HIV with educational content aimed at raising awareness and fostering greater understanding in our community.
We’ll be sharing information on our socials and patientworthy.com to educate, empower, and support those affected.
If you'd like to share your story with HIV, click here: bit.ly/4dV7gru
#HumanImmunodeficiencyVirus #HIV #HIVAwareness #ShareYourStory #PatientWorthy
